Applied Sports Science Technology and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, Swansea, UK.
School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland.
Complement Ther Med. 2020 May;50:102349. doi: 10.1016/j.ctim.2020.102349. Epub 2020 Feb 19.
Osteoarthritis (OA) is characterised by synovial joint pain, functional disability and affects ∼13 % of people worldwide, of which ∼16-27 % report Knee-OA (KOA). Glucosamine (Glu) is the most widely used nutraceutical treatment for OA despite a lack of scientific consensus, therefore alternative nutraceutical treatments are required. The aim of this study was to investigate the effect of Lithothamnion species, seawater-derived magnesium and pine bark (Aq) on pain, symptoms and improve physical function in symptomatic (sKOA), compared to Glu.
358 participants were screened. In a double-blinded crossover pilot-trial, sKOA participant (n = 30) were randomly assigned to either the Glu group (2000 mg day) or Aq (3056 mg day) for 12 weeks (clinicaltrials.gov:NCT03106584). The Knee Injury and Osteoarthritis Outcome Score was used to assess subjective pain and symptoms. Timed-up-and-Go (TuG) and Six minute walking distance were used to assess functional change and analgesic use was recorded.
Aq improved pain, with a large effect (P < 0.01, d' = 0.73, 95 %CI 0.201-1.265) and no change for Glu (d' = 0.38, P = 0.06). Only Aq improved pain (P < 0.05) for males (d' = 0.91, 95 %CI 0.162-1.667) and females (d' = 0.55, 95 %CI 0.210-1.299). In females, Aq improved TuG by -7.02 % (d' = 0.92, 95 %CI 1.699-0.141) while Glu worsened performance by 4.18 % (P = 0.04). Aq reduced analgesia by 71.6 %, compared to Glu (P = 0.02; d' = 0.82, 95 %CI 1.524-0.123). Aq was superior to Glu at improving pain, KOOS subscales, physical function and analgesia use in mild-sKOA. Given these data, Aq should be considered as a supplementary treatment for early-stage-KOA and may have the potential to reduce use of pain medication, although larger replication studies are required.
骨关节炎（OA）的特征是滑膜关节疼痛、功能障碍，影响全球约 13%的人群，其中约 16-27%的人报告膝关节 OA（KOA）。尽管缺乏科学共识，葡萄糖胺（Glu）仍然是最广泛使用的治疗 OA 的营养保健品，因此需要替代的营养保健品治疗。本研究旨在调查 Lithothamnion 物种、海水衍生的镁和松树皮（Aq）对有症状（sKOA）的疼痛、症状和改善身体功能的影响，与 Glu 相比。
筛选了 358 名参与者。在一项双盲交叉先导试验中，sKOA 参与者（n = 30）随机分配至 Glu 组（2000 mg/天）或 Aq 组（3056 mg/天），治疗 12 周（clinicaltrials.gov：NCT03106584）。使用膝关节损伤和骨关节炎结果评分评估主观疼痛和症状。使用计时起立行走测试（TuG）和六分钟步行距离评估功能变化，并记录镇痛药使用情况。
Aq 改善了疼痛，具有较大的效果（P < 0.01，d' = 0.73，95%CI 0.201-1.265），而 Glu 无变化（d' = 0.38，P = 0.06）。只有 Aq 改善了男性（d' = 0.91，95%CI 0.162-1.667）和女性（d' = 0.55，95%CI 0.210-1.299）的疼痛。在女性中，Aq 使 TuG 改善了-7.02%（d' = 0.92，95%CI 1.699-0.141），而 Glu 则使性能恶化了 4.18%（P = 0.04）。与 Glu 相比，Aq 减少了 71.6%的镇痛药使用（P = 0.02；d' = 0.82，95%CI 1.524-0.123）。在轻度 sKOA 中，Aq 在改善疼痛、KOOS 亚量表、身体功能和镇痛药使用方面优于 Glu。鉴于这些数据，Aq 应被视为早期 KOA 的辅助治疗方法，并且可能有潜力减少疼痛药物的使用，尽管需要更大的复制研究。
